> News > Mymetics Virosomes Successful in Allergy Proof-of-Concept Study
13.12
2018

Mymetics Virosomes Successful in Allergy Proof-of-Concept Study

Epalinges, Switzerland, December 13, 2018 – Mymetics Corporation (OTCQB: MYMX), a pioneer and leader in the research and development of virosome-based vaccines against life threatening and life disabling diseases, announced today that the pre-clinical proof-of-concept study for allergies, with their partner Anergis SA, has met the success criteria.
The mice proof-of-concept immunogenicity study evaluated the effects of the Bet v 1 COPs (Anergis’ proprietary birch pollen allergy peptides) using the five subcutaneous injection schedule used in former AllerT clinical trials. The development of AllerT (Bet v 1 COPs plus aluminum hydroxide) was discontinued by Anergis in 2017 following completion of a Phase 2 clinical trial showing evidence of sensitization to the peptides and a 7% reduction in seasonal allergy symptoms vs placebo (p=0.0047).

Read full press release